Balance Sheet
Cash Flow Statement
Daily Values
DMA 100DMA 200DMA 50Dividend YieldEV to CFOEV to EBITEV to EBITDAEV to FCFEV to RevenueEnterprise ValueMarket Cap to FCFMarket CapitalizationPricePrice to EarningsPrice to Sales
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Envoy Medical (COCH) Enterprise Value (2022 - 2026)

Envoy Medical's Enterprise Value history spans 5 years, with the latest figure at -$25.3 million for Q1 2026.

  • On a quarterly basis, Enterprise Value fell 375.36% to -$25.3 million in Q1 2026 year-over-year; TTM through Mar 2026 was -$25.3 million, a 375.36% decrease, with the full-year FY2025 number at -$3.7 million, up 31.81% from a year prior.
  • Enterprise Value hit -$25.3 million in Q1 2026 for Envoy Medical, down from -$3.7 million in the prior quarter.
  • Over the last five years, Enterprise Value for COCH hit a ceiling of -$68000.0 in Q2 2023 and a floor of -$25.3 million in Q1 2026.
  • Historically, Enterprise Value has averaged -$5.5 million across 5 years, with a median of -$4.0 million in 2023.
  • Biggest five-year swings in Enterprise Value: plummeted 7264.31% in 2023 and later surged 80.11% in 2024.
  • Tracing COCH's Enterprise Value over 5 years: stood at -$183000.0 in 2022, then plummeted by 2205.46% to -$4.2 million in 2023, then fell by 29.96% to -$5.5 million in 2024, then surged by 31.81% to -$3.7 million in 2025, then plummeted by 575.34% to -$25.3 million in 2026.
  • Business Quant data shows Enterprise Value for COCH at -$25.3 million in Q1 2026, -$3.7 million in Q4 2025, and -$3.6 million in Q3 2025.